Early Effects of Initiating Gender Affirming Hormone Therapy on BMI in Transgender Adolescents and Young Adults by Futcher, Regina & Grooms, Kaley
Early Effects of Initiating Gender Affirming Hormone Therapy on BMI 
on Transgender Adolescents and Young Adults
Futcher R2, Grooms K2, Sequeira G1,2, El Nokali N2, Levine M2, Miller E1,2, Austin SB3, Rofey D2. 1 Children’s Hospital of Pittsburgh 2 
University of Pittsburgh 3Boston Children's Hospital
Background
Conclusions
Limitations
Methods
Future Directions
•Previous studies have shown a relationship 
between body weight increase and masculinizing 
and feminizing hormone therapy in transgender 
adults
•Not much is known about the effects gender 
affirming hormone therapy may have on BMI in 
adolescents and young adults (AYA)
Text
• The dosage and route of Gender Affirming 
Hormones varied and was not held constant. 
(According to patient preference and doctor 
recommendation)
• There were differences in baseline BMI due to wide 
age range
• Age was not held constant
• Measures of adiposity (obesity) and bone density 
were not directly taken, only from BMI•Participants consisted of transgender patients aged 
13 to 26 receiving gender affirming hormone 
therapy.
•Masculinizing hormone therapy includes 
transdermal, subcutaneous or intramuscular 
testosterone
•Feminizing hormone therapy includes oral, 
transdermal or intramuscular estradiol ±
spironolactone
•Retrospective observational data was collected via 
electronic health records (correlational study)
•Paired t-tests were used to compare BMI %tile and 
BMI z-score at baseline and 6 month follow up
•BMI z-score was calculated using CDC growth charts 
given wide age range
•Ongoing repeated measures analysis with additional 
follow up weights
•Further investigation into long term effects on 
adiposity, lean tissue, and bone density
•Understanding eating behaviors and physical 
movement may be important in determining the basis 
for BMI change
• A more careful description of age, hormone dose, 
and rate of weight gain will be important in the 
development of standards for gender affirming care in 
the future. 
•AYA receiving masculinizing hormone therapy had 
a significant increase in BMI %tile and BMI z-score 
at 6 month follow up (p<0.05) (small p value means 
significant) 
•No differences were seen in BMI %tile or BMI z-
score in AYA receiving feminizing hormone therapy 
at 6 month follow up (p>0.05)
• Adolescents receiving masculinizing 
hormones showed a significant increases in 
BMI %tile and BMI z-score
•Close monitoring of adiposity and bone 
density may be important in the clinical care 
of youth receiving masculinizing hormones 
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